Cite
Goswami S, Mani R, Nunes J, et al. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia. Blood. 2021;doi: 10.1182/blood.2020010344.
Goswami, S., Mani, R., Nunes, J., Chiang, C. L., Zapolnik, K., Hu, E. Y., Frissora, F. W., Mo, X. M., Walker, L. A., Yan, P. S., Bundschuh, R., Beaver, L., Devine, R. D., Tsai, Y. T., Ventura, A. M., Xie, Z., Chen, M., Lapalombella, R., Walker, A. R., Mims, A. S., Larkin, K., Grieselhuber, N. R., Bennett, C., Phelps, M. A., Hertlein, E., Behbehani, G. K., Vasu, S., Byrd, J. C., & Muthusamy, N. (2021). PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia. Blood, . https://doi.org/10.1182/blood.2020010344
Goswami, Swagata, et al. "PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2020010344
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu EY, Frissora FW, Mo XM, Walker LA, Yan PS, Bundschuh R, Beaver L, Devine RD, Tsai YT, Ventura AM, Xie Z, Chen M, Lapalombella R, Walker AR, Mims AS, Larkin K, Grieselhuber NR, Bennett C, Phelps MA, Hertlein E, Behbehani GK, Vasu S, Byrd JC, Muthusamy N. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia. Blood. 2021 Nov 17; doi: 10.1182/blood.2020010344. Epub 2021 Nov 17. PMID: 34788382.
Copy
Download .nbib